This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Rituxan
  • /
  • A Phase 1/2 Study Of CMC-544 Administered In Combi...
Clinical trial

A Phase 1/2 Study Of CMC-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Read time: 2 mins
Last updated:1st May 2006
Identifier: NCT00299494

The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin [CMC-544] in combination with rituximab in subjects with follicular, diffuse large B-Cell, or mantle cell NHL.

Category Value
Date last updated at source 2015-10-06
Study type(s) Interventional
Expected enrolment 119
Study start date 2006-05-01
Estimated primary completion date 2014-06-01

View full details